Baidu
map

药明生物和誉衡药业将PD-1抗体GLS-010授权给Arcus Biosciences

2017-08-22 佚名 MedSci原创

-药明生物和誉衡药业将全人创新PD-1抗体GLS-010的国际权益授权给Arcus Biosciences

上海和北京2017年8月17日电 /美通社/ -- 药明生物(2269.HK)与其中国合作伙伴誉衡药业(002437.CN)今日宣布,将全人创新PD-1抗体GLS-010的国际权益独家授权给专注于研发创新肿瘤免疫疗法的美国生物技术公司Arcus Biosciences。

誉衡药业委托药明生物使用从美国Ligand Pharmaceuticals公司引进的全球领先的转基因大鼠平台OmniRat®开发了PD-1全人创新抗体药物GLS-010,目前该药正在中国开展肿瘤治疗的I期临床试验。通过此次合作,Arcus将获得GLS-010在北美、欧洲、日本及一些其他地区的独家开发和商业化权益。

Arcus计划以GLS-010与其他候选产品进行肿瘤免疫组合疗法的开发并支付1850万美元的前期许可费。针对含GLS-010的11个组合产品的开发、批准注册,药明生物和誉衡药业可获得最多4.225亿美元里程碑付款,同时还将有权获得最多3.75亿美元的商业化里程碑付款,总合同金额最高可达8.16亿美元。双方还将享有产品上市后净销售额最高10%左右的销售提成。此外,Arcus还将与药明生物签订三年排他性服务协议合作开发其全部生物药产品管线,药明生物在一定期限内成为Arcus公司GLS-010获权范围内的独家生产服务商。

“我们非常荣幸药明生物打造的全球领先的开放式生物制药技术平台能助力誉衡药业这样的中国本土企业以一个令人振奋的项目为起点全面进军生物制药领域,并通过此次合作加快中国创新生物药的海内外开发进程,让全球病患受益。”药明生物首席执行官兼执行董事陈智胜博士表示,“新的合作伙伴关系再次彰显药明生物高效的一站式服务的商业模式,对合作伙伴最高的质量承诺,以及药明生物‘跟随药物分子发展阶段扩大业务’这一商业策略的重要价值。”

Arcus公司商业发展副总裁Tim Sullivan博士表示:“我们很高兴能获得GLS-010在这些地区的开发和商业化授权,该药将促进我们公司其他肿瘤免疫疗法新药的潜力最大化,造福更多病患。Arcus致力于开发一系列创新药及最优联合疗法用于肿瘤治疗,药明生物快速生产高质量的临床试验样品为我们提供了强有力的支持,将有助于公司实现战略目标。”

“誉衡药业近期的研发逐步聚焦生物制药,尤其是免疫肿瘤治疗领域。我们希望通过我们的努力使越来越多的生物新药进入中国市场,解决未被满足的临床需求,”誉衡药业总经理杨红冰先生指出,“这是誉衡药业的生物药首次参与全球性的合作,我们很荣幸能与药明生物携手Arcus,共同加速为中国及全世界患者提供创新肿瘤疗法。”

关于GLS-010

GLS-010(WBP3055)属于“免疫检查点”抑制剂的肿瘤免疫药物,是由国内研发机构完成临床试验申报的首个全人PD-1单克隆抗体,作用机制是与细胞表面的可抑制T细胞活化的PD-1 受体结合,阻断负向调节作用,激发免疫细胞对肿瘤细胞的免疫应答,从而杀伤肿瘤细胞。同时,该药具有治疗多种类型肿瘤的潜力,有望成为一款广谱抗肿瘤药物。国际上已上市的PD-1单抗药经FDA批准用于多种肿瘤疾病的治疗。据统计,目前PD-1抗体药在全球有500多个临床试验被用于20多种肿瘤适应证的研究。

药明生物

药明生物是全球领先的开放式、一体化生物制药能力和技术平台,为全球生物制药公司和生物技术公司提供全方位的端到端研发服务,帮助任何人、任何公司发现、开发及生产生物药,实现从概念到商业化生产的全过程,加速全球生物药研发进程,降低研发成本,造福病患。更多信息,请访问:http://www.wuxibiologics.com.cn/

誉衡药业

誉衡药业总部位于北京,是中国领先的制药企业,坚持“产品领先”战略,通过外延并购、合作代理、自主研发、海外引进等多种方式丰富公司产品线,实现了由上市初狭窄单一的骨科治疗领域向现有心脑血管等大治疗领域的拓展,形成了包括心脑血管领域、骨骼肌肉领域、营养用药领域等多个重磅级产品集群,多产品驱动业绩增长的新格局逐步显现。更多信息,请访问:www.gloria.cc

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1917618, encodeId=80fc191e61840, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 25 15:00:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375666, encodeId=574f13e5666ba, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577085, encodeId=7fdb15e708531, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13914, encryptionId=a2a613914cd, topicName=PD-1抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=021d16387966, createdName=1249857fm37暂无昵称, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581587, encodeId=d543158158e12, content=<a href='/topic/show?id=22a08e6050d' target=_blank style='color:#2F92EE;'>#药明生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87605, encryptionId=22a08e6050d, topicName=药明生物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3e016837754, createdName=ms7421025882867189, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=)]
    2017-10-25 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1917618, encodeId=80fc191e61840, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 25 15:00:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375666, encodeId=574f13e5666ba, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577085, encodeId=7fdb15e708531, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13914, encryptionId=a2a613914cd, topicName=PD-1抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=021d16387966, createdName=1249857fm37暂无昵称, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581587, encodeId=d543158158e12, content=<a href='/topic/show?id=22a08e6050d' target=_blank style='color:#2F92EE;'>#药明生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87605, encryptionId=22a08e6050d, topicName=药明生物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3e016837754, createdName=ms7421025882867189, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=)]
    2017-08-24 jichang
  3. [GetPortalCommentsPageByObjectIdResponse(id=1917618, encodeId=80fc191e61840, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 25 15:00:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375666, encodeId=574f13e5666ba, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577085, encodeId=7fdb15e708531, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13914, encryptionId=a2a613914cd, topicName=PD-1抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=021d16387966, createdName=1249857fm37暂无昵称, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581587, encodeId=d543158158e12, content=<a href='/topic/show?id=22a08e6050d' target=_blank style='color:#2F92EE;'>#药明生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87605, encryptionId=22a08e6050d, topicName=药明生物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3e016837754, createdName=ms7421025882867189, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1917618, encodeId=80fc191e61840, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 25 15:00:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375666, encodeId=574f13e5666ba, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577085, encodeId=7fdb15e708531, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13914, encryptionId=a2a613914cd, topicName=PD-1抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=021d16387966, createdName=1249857fm37暂无昵称, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581587, encodeId=d543158158e12, content=<a href='/topic/show?id=22a08e6050d' target=_blank style='color:#2F92EE;'>#药明生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87605, encryptionId=22a08e6050d, topicName=药明生物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3e016837754, createdName=ms7421025882867189, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=)]

相关资讯

不谈“硒”色变 要科学识“硒”、补“硒”

大医编发布了有关科学认识“硒”以及人们该如何正确补“硒”的文章,帮助人们建立对“硒”元素的正确认识。

三生制药累计捐赠价值1.5亿生物药 惠及千万风湿疾病患者

2017年8月19日,由北京白求恩公益基金会与三生制药共同发起的2017年度“益+希望-白求恩·益赛普®公益捐助项目”在江西井冈山启动

Baidu
map
Baidu
map
Baidu
map